An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

Abstract:

AIM:Tamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor α/β. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetics, efficacy, and safety profiles for advanced hepatocellular carcinoma (HCC). METHODS:Patients with histologically confirmed, measurable, unresectable HCC of Child-Pugh classification A or B and with no effective systemic or local therapies were eligible. In phase I, patients were assigned based on the 3 + 3 dose escalation criteria to receive tamibarotene at 8, 12, and 16 mg/day. The RD determined in phase I was employed for phase II. The planned sample size in phase II was 25, including the RD-treated patients in phase I. RESULTS:Thirty-six patients were enrolled. No patients experienced dose-limiting toxicity (DLT) at 8 mg/day. However, two out of six patients experienced the DLTs at 12 mg/day: one experienced thrombosis in a limb vein and pulmonary artery, and the other experienced an increase of γ-GTP. The MTD and RD were determined as 12 and 8 mg/day, respectively. In phase II, one patient achieved partial response, and seven achieved stable disease. The disease control rate was 32 % (95 % CI: 15.0-53.5). The following drug-related serious adverse events were reported: thrombosis in a limb vein, pulmonary artery, and portal vein; interstitial lung disease; and vomiting. CONCLUSIONS:Tamibarotene demonstrated the inhibition of tumor cell growth in advanced HCC with acceptable tolerance.

journal_name

Hepatol Int

journal_title

Hepatology international

authors

Kanai F,Obi S,Fujiyama S,Shiina S,Tamai H,Mochizuki H,Koike Y,Imamura J,Yamaguchi T,Saida I,Yokosuka O,Omata M

doi

10.1007/s12072-013-9459-7

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

94-103

issue

1

eissn

1936-0533

issn

1936-0541

pii

10.1007/s12072-013-9459-7

journal_volume

8

pub_type

杂志文章
  • Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients.

    abstract:BACKGROUND AND OBJECTIVE:Cytokines have been reported to be involved in the cirrhosis and hepatic encephalopathy (HE). Many aspects on the correlation between minimal HE (MHE) and cytokine levels were still unclear. METHODS:Two hundred eighty-nine HBV-infected cirrhotic patients were grouped: non MHE (n = 156), MHE (n...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-015-9610-8

    authors: Li W,Li N,Wang R,Li Q,Wu H

    更新日期:2015-04-01 00:00:00

  • Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis.

    abstract:BACKGROUND/PURPOSE:Gut microbiota has been associated with liver cirrhosis and, possibly, hepatic encephalopathy. However, only a few studies have examined the link between mucosa-associated microbiota (MAM) and minimal hepatic encephalopathy (MHE). Our aim was to investigate this relationship. METHODS:Twenty-four pat...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-09963-2

    authors: Haraguchi M,Miuma S,Masumoto H,Ichikawa T,Kanda Y,Sasaki R,Fukushima M,Miyaaki H,Taura N,Nakao K

    更新日期:2019-07-01 00:00:00

  • Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.

    abstract:PURPOSE:We investigated whether the combined presence and evolution of hepatitis B virus (HBV) mutant strains in the hepatitis B e antigen (HBeAg)-positive status can predict clinical outcomes after HBeAg seroconversion. METHODS:One hundred and eighty-six patients with spontaneous HBeAg seroconversion were enrolled in...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9381-4

    authors: Chen CH,Lee CM,Wang JH,Hu TH,Hung CH,Changchien CS,Lu SN

    更新日期:2013-06-01 00:00:00

  • Epigenetic histone modifications in a clinically relevant rat model of chronic ethanol-binge-mediated liver injury.

    abstract:PURPOSE:Ethanol binge augments liver injury after chronic ethanol consumption in humans, but the mechanism behind the enhanced liver injury by ethanol binge is not known. In this study we used a clinically relevant rat model in which liver injury is amplified by binge after chronic ethanol treatment and investigated th...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-014-9546-4

    authors: Aroor AR,Restrepo RJ,Kharbanda KK,Shukla SD

    更新日期:2014-09-01 00:00:00

  • The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH).

    abstract:BACKGROUND AND AIMS:The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatit...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9395-y

    authors: Kakazu E,Kondo Y,Ninomiya M,Kimura O,Nagasaki F,Ueno Y,Shimosegawa T

    更新日期:2013-06-01 00:00:00

  • Procaine inhibits the proliferation and DNA methylation in human hepatoma cells.

    abstract:PURPOSE:Transcriptional silencing of tumor suppressor genes associated with DNA hypermethylation has been known as a hallmark of human cancer. In this study, we revealed that a local anesthetic, procaine (PCA), possessed growth-inhibitory and demethylating effect on human hepatoma cells in vitro and in vivo. METHODS:T...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-007-9014-5

    authors: Tada M,Imazeki F,Fukai K,Sakamoto A,Arai M,Mikata R,Tokuhisa T,Yokosuka O

    更新日期:2007-09-01 00:00:00

  • Genetic and epigenetic mechanisms of NASH.

    abstract::Along with the obesity epidemic, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased exponentially. The histological disease spectrum of NAFLD ranges from bland fatty liver (hepatic steatosis), to the concomitant presence of inflammation and ballooning which defines nonalcoholic steatohepatitis (N...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-015-9689-y

    authors: Eslam M,George J

    更新日期:2016-05-01 00:00:00

  • p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.

    abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is one of the most common malignant neoplasms worldwide. The p53 gene is frequently mutated in some histological subtypes of HCC. The role of p53 mutations and polymorphic variant of codon 72 in the prognosis of disease is still unclear. The p53 tumor suppressor gene Arg72Pro p...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9389-9

    authors: Jia S,Tang W,Luo Y

    更新日期:2013-06-01 00:00:00

  • A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.

    abstract:PURPOSE:Clevudine 30 mg showed potent antiviral activity with a marked post-treatment antiviral effect. However, long-term treatment with clevudine monotherapy induced resistance and myopathy in some cases. The objective of this study is to evaluate the preliminary efficacy and safety of the combination of clevudine 20...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-014-9537-5

    authors: Tak WY,Yang JM,Kim BI,Baik SK,Cheon GJ,Byun KS,Kim DY,Yoo BC

    更新日期:2014-05-25 00:00:00

  • Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.

    abstract:PURPOSE:Lamivudine treatment of chronic hepatitis B (CHB) is associated with frequent resistance and loss of clinical benefit. We present outcomes of lamivudine-refractory Japanese patients treated with entecavir for 3 years. METHODS:Eighty-two patients refractory to lamivudine therapy received entecavir 0.5 or 1 mg d...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-009-9162-x

    authors: Karino Y,Toyota J,Kumada H,Katano Y,Izumi N,Kobashi H,Sata M,Moriyama M,Imazeki F,Kage M,Ishikawa H,Masaki N,Seriu T,Omata M

    更新日期:2010-02-06 00:00:00

  • Effect of hepatitis B surface antibody in patients with core antibody-positive liver transplantation: a systematic review and meta-analysis.

    abstract:BACKGROUND AND AIM:There is an increased awareness of de novo hepatitis B virus (HBV) infection (DNH) in hepatitis B surface antigen (HBsAg)-negative recipients receiving hepatitis B core antibody (HBcAb)-positive liver organ. Whether hepatitis B surface antibody (HBsAb) has positive result on preventing the occurrence...

    journal_title:Hepatology international

    pub_type: 杂志文章,meta分析

    doi:10.1007/s12072-020-10021-5

    authors: Yang Y,Huang A,Zhao Y

    更新日期:2020-03-01 00:00:00

  • MSC-based therapies in solid organ transplantation.

    abstract::Immunomodulatory cell therapy as a complement to standard pharmacotherapy represents a novel approach to solid organ allograft acceptance. This methodology may allow for a reduced dose of immunosuppressive drug to be administered and thus attenuate the severe side effects associated with long-term immunosuppression su...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9509-1

    authors: Benseler V,Obermajer N,Johnson CL,Soeder Y,Dahlke MD,Popp FC

    更新日期:2014-04-01 00:00:00

  • HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.

    abstract:BACKGROUND:Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). This phase IV study assessed sorafenib efficacy/safety in Taiwanese patients with advanced HCC and Child-Pugh A status. METHODS:All patients received 400 mg sorafenib BID. Safety, efficacy, sorafenib pharmaco...

    journal_title:Hepatology international

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s12072-016-9774-x

    authors: Lin SM,Lu SN,Chen PT,Jeng LB,Chen SC,Hu CT,Yang SS,Le Berre MA,Liu X,Mitchell DY,Prins K,Grevel J,Peña CA,Meinhardt G

    更新日期:2017-03-01 00:00:00

  • Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion.

    abstract:PURPOSE:Microvascular invasion of hepatocellular carcinoma (HCC) is considered a poor prognostic factor of liver resection (LR) and liver transplantation (LT), but its significance for lesions within the up-to-7 criteria is unclear. This study investigated the survival benefit of primary LT against LR for HCC with micr...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-011-9318-3

    authors: Chan SC,Fan ST,Chok KS,Cheung TT,Chan AC,Fung JY,Poon RT,Lo CM

    更新日期:2011-10-21 00:00:00

  • New therapeutic targets in alcoholic hepatitis.

    abstract::Alcoholic liver disease (ALD) is a leading cause of liver-related morbidity and mortality worldwide. ALD encompasses a spectrum of disorders including asymptomatic steatosis, steatohepatitis, fibrosis, cirrhosis and its related complications, and the acute-on-chronic state of alcoholic hepatitis. While multidisciplina...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-015-9701-6

    authors: Arsene D,Farooq O,Bataller R

    更新日期:2016-07-01 00:00:00

  • Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models.

    abstract:BACKGROUND AND AIMS:Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models. METHODS:A ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-017-9816-z

    authors: Choudhury A,Jindal A,Maiwall R,Sharma MK,Sharma BC,Pamecha V,Mahtab M,Rahman S,Chawla YK,Taneja S,Tan SS,Devarbhavi H,Duan Z,Yu C,Ning Q,Jia JD,Amarapurkar D,Eapen CE,Goel A,Hamid SS,Butt AS,Jafri W,Kim DJ,G

    更新日期:2017-09-01 00:00:00

  • Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis.

    abstract:BACKGROUND AND AIMS:Coronavirus disease 2019 (COVID-19) pandemic is ongoing. Except for lung injury, it is possible that COVID-19 patients develop liver injury. Thus, we conducted a systematic review and meta-analysis to explore the incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 ...

    journal_title:Hepatology international

    pub_type: 杂志文章,meta分析

    doi:10.1007/s12072-020-10074-6

    authors: Wu Y,Li H,Guo X,Yoshida EM,Mendez-Sanchez N,Levi Sandri GB,Teschke R,Romeiro FG,Shukla A,Qi X

    更新日期:2020-09-01 00:00:00

  • A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.

    abstract::In a country such as Japan with the average age of patients with chronic hepatitis C treated with antivirals sometimes well above 60 years, the standard combination therapy is not well tolerated. In this randomized, prospective, controlled trial, we investigated the efficacy of 24-week peginterferon α monotherapy for ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-009-9134-1

    authors: Iwasaki Y,Shiratori Y,Hige S,Nishiguchi S,Takagi H,Onji M,Yoshida H,Izumi N,Kohgo Y,Yamamoto K,Sato N,Shibuya A,Saito H,Sata M,Suzuki K,Kaneko S,Moriyama M,Omata M

    更新日期:2009-09-01 00:00:00

  • Obstructive jaundice promotes intestinal-barrier dysfunction and bacterial translocation: experimental study.

    abstract:BACKGROUND:Although clinical and experimental studies have demonstrated a correlation between obstructive jaundice and the development of sepsis, the mechanism has not been fully elucidated. PURPOSE:The aim of this study was to investigate the influence of biliary obstruction on bacterial translocation as a possible s...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-007-9018-1

    authors: Abdeldayem H,Ghoneim E,Refaei AA,Abou-Gabal A

    更新日期:2007-12-01 00:00:00

  • The prevalence of occult HBV infection in immunized children with HBsAg-positive parents: a hospital-based analysis.

    abstract:BACKGROUND AND OBJECT:The risk of occult HBV infection (OBI) in children whose mothers are HBV carriers has received more widespread attention, but there were few reports to focus on the children with HBsAg-positive parents. In this study, we aimed to investigate the prevalence of OBI in immunized children with HBsAg-p...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-020-10055-9

    authors: Zhuge S,Ge C,Yang Y,Cui Y,Yue X,Zhang Z,Xu H,Huang A,Zhao Y

    更新日期:2020-07-01 00:00:00

  • Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.

    abstract:BACKGROUND AND AIM:Relationships between circulating microRNA-122 (miR-122) and histological features of nonalcoholic fatty liver disease (NAFLD) are unclear. METHODS:The impact of serum miR-122 levels for histological features and hepatocellular carcinoma (HCC) was investigated in 305 Japanese patients with histologi...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-016-9729-2

    authors: Akuta N,Kawamura Y,Suzuki F,Saitoh S,Arase Y,Kunimoto H,Sorin Y,Fujiyama S,Sezaki H,Hosaka T,Kobayashi M,Suzuki Y,Kobayashi M,Ikeda K,Kumada H

    更新日期:2016-07-01 00:00:00

  • A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients.

    abstract:PURPOSE:To compare the efficacy of entecavir (ETV) monotherapy up to 4 years in nucleos(t)ide analog (NA)-experienced and -naïve subjects. METHODS:One hundred sixty NA-experienced and 282 naïve chronic hepatitis B patients who were treated with ETV were enrolled. Of the 160 NA-experienced patients, 49 had prior lamivu...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9440-5

    authors: Chen CH,Hu TH,Hung CH,Lu SN,Wang JH,Chang MH,Changchien CS,Lee CM

    更新日期:2013-07-01 00:00:00

  • Cirrhotic cardiomyopathy.

    abstract::Cirrhotic cardiomyopathy is a recently recognized condition in cirrhosis consisting of systolic incompetence under condition of stress, diastolic dysfunction related to altered diastolic relaxation, and electrophysiological abnormalities in the absence of any known cardiac disease. It can be diagnosed by using a combi...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-008-9109-7

    authors: Wong F

    更新日期:2009-03-01 00:00:00

  • Chinese guidelines on the management of ascites and its related complications in cirrhosis.

    abstract::The Chinese Society of Hepatology developed the current guidelines for the Management of Ascites and Its Related Complications in Cirrhosis based on the published evidences and the panelists' consensus. The guidelines provided recommendations for the diagnosis and management of cirrhotic ascites emphasizing a step-wis...

    journal_title:Hepatology international

    pub_type: 社论,实务指引

    doi:10.1007/s12072-018-09923-2

    authors: Chinese Society of Hepatology, Chinese Medical Association.,Xu X,Duan Z,Ding H,Li W,Jia J,Wei L,Linghu E,Zhuang H

    更新日期:2019-01-01 00:00:00

  • Reversal of NASH fibrosis with pharmacotherapy.

    abstract::NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epi...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-019-09970-3

    authors: Alukal JJ,Thuluvath PJ

    更新日期:2019-09-01 00:00:00

  • Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.

    abstract:BACKGROUND AND AIMS:T cell-mediated immune injury plays a critical role in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Given the high short-term mortality and crucial role of T cells in the disease progression, it is necessary to investigate the dynamics of T cell clones dur...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-10008-x

    authors: Shen G,Sun S,Huang J,Deng H,Xu Y,Wang Z,Tang X,Gong X

    更新日期:2020-01-01 00:00:00

  • Association of the Laennec staging system with degree of cirrhosis, clinical stage and liver function.

    abstract:OBJECTIVES:The aim of this study was to investigate the association of the Laennec staging system with degree of cirrhosis, clinical stage and liver function. METHODS:Liver biopsy was performed for 30 patients with hepatitis B cirrhosis to test the content of hydroxyproline in hepatic tissue, judge the degree of cirrh...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-015-9648-7

    authors: Wang W,Li J,Pan R,A S,Liao C

    更新日期:2015-10-01 00:00:00

  • Hepatic encephalopathy in acute-on-chronic liver failure.

    abstract::The presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining acute-on-chronic liver failure (ACLF). The pathophysiology of HE is complex, and hyperammonemia and cerebral hemodynamic dysfunction appear to be central in the pathogenesis of encephalopathy. Recent data also suggest that ...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-015-9626-0

    authors: Lee GH

    更新日期:2015-10-01 00:00:00

  • Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance.

    abstract:BACKGROUND:Initial presentation of hepatocellular carcinoma (HCC) at an advanced stage in patients under a regular surveillance program is a devastating problem. AIMS:We assessed the prevalence and factors associated with this surveillance failure. METHODS:A total of 304 HCC patients who received regular surveillance...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9462-z

    authors: Sinn DH,Yi J,Choi MS,Choi D,Gwak GY,Paik YH,Lee JH,Koh KC,Paik SW,Yoo BC

    更新日期:2013-10-01 00:00:00

  • Hepatocellular adenoma: what is new in 2008.

    abstract::Patients (85%) with hepatocellular adenoma (HCA) are women taking oral contraceptives. They can be divided into four subgroups according to their genotype/phenotype features. (1) Hepatocyte nuclear factor 1alpha (HNF1alpha) biallelic somatic mutations are observed in 35% of the HCA cases. It occurs in almost all cases...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-008-9075-0

    authors: Bioulac-Sage P,Laumonier H,Laurent C,Zucman-Rossi J,Balabaud C

    更新日期:2008-09-01 00:00:00